Dose-Dependent Protection against or Exacerbation of Disease by a Polylactide Glycolide Microparticle-Adsorbed, Alphavirus-Based Measles Virus DNA Vaccine in Rhesus Macaques
Open Access
- 1 April 2008
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (4) , 697-706
- https://doi.org/10.1128/cvi.00045-08
Abstract
Measles remains an important cause of vaccine-preventable child mortality. Development of a low-cost, heat-stable vaccine for infants under the age of 6 months could improve measles control by facilitating delivery at the time of other vaccines and by closing a window of susceptibility prior to immunization at 9 months of age. DNA vaccines hold promise for development, but achieving protective levels of antibody has been difficult and there is an incomplete understanding of protective immunity. In the current study, we evaluated the use of a layered alphavirus DNA/RNA vector encoding measles virus H (SINCP-H) adsorbed onto polylactide glycolide (PLG) microparticles. In mice, antibody and T-cell responses to PLG-formulated DNA were substantially improved compared to those to naked DNA. Rhesus macaques received two doses of PLG/SINCP-H delivered either intramuscularly (0.5 mg) or intradermally (0.5 or 0.1 mg). Antibody and T-cell responses were induced but not sustained. On challenge, the intramuscularly vaccinated monkeys did not develop rashes and had lower viremias than vector-treated control monkeys. Monkeys vaccinated with the same dose intradermally developed rashes and viremia. Monkeys vaccinated intradermally with the low dose developed more severe rashes, with histopathologic evidence of syncytia and intense dermal and epidermal inflammation, eosinophilia, and higher viremia compared to vector-treated control monkeys. Protection after challenge correlated with gamma interferon-producing T cells and with early production of high-avidity antibody that bound wild-type H protein. We conclude that PLG/SINCP-H is most efficacious when delivered intramuscularly but does not provide an advantage over standard DNA vaccines for protection against measles.Keywords
This publication has 69 references indexed in Scilit:
- Hemagglutinin Protein Is a Primary Target of the Measles Virus–Specific HLA‐A2–Restricted CD8+T Cell Response during Measles and after VaccinationThe Journal of Infectious Diseases, 2007
- Relative Contributions of Measles Virus Hemagglutinin- and Fusion Protein-Specific Serum Antibodies to Virus NeutralizationJournal of Virology, 2005
- Protection against Challenge with Measles Virus (MV) in Infant Macaques by an MV DNA Vaccine Administered in the Presence of Neutralizing AntibodyThe Journal of Infectious Diseases, 2004
- Comparison of Vaccination with Measles-Mumps-Rubella Vaccine at 9, 12, and 15 Months of AgeThe Journal of Infectious Diseases, 2004
- Differential Effects of Priming with DNA Vaccines Encoding the Hemagglutinin and/or Fusion Proteins on Cytokine Responses after Measles Virus ChallengeThe Journal of Infectious Diseases, 2003
- Alphavirus cDNA-based expression vectors: Effects of RNA transcription and nuclear exportBiotechnology & Bioengineering, 2003
- Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cellsGene Therapy, 2000
- The 1st International Standard for anti-measles serumBiologicals, 1991
- Measles Virus Fusion Protein Presented in an Immune-stimulating Complex (Iscom) Induces Haemolysis-inhibiting and Fusion-inhibiting Antibodies, Virus-specific T Cells and Protection in MiceJournal of General Virology, 1988
- Persistence of maternal antibody in infants beyond 12 months: Mechanism of measles vaccine failureThe Journal of Pediatrics, 1977